Showing results (1691-1700 of 1,756) with videos related to
Sort By:
Pageof 176
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|January 11, 2013
[A clinical study on multi-disciplinary team and surgery for resectable colorectal cancer with liver metastases]Hong-Wei Yao, Dian-rong Xiu, Wei Fu, et al.Nature Cell Biology|July 25, 2018
Publisher Correction: Tracing the temporal-spatial transcriptome landscapes of the human fetal digestive tract using single-cell RNA-sequencingShuai Gao, Liying Yan, Rui Wang, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2021
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or EnzalutamideKatherine A Zukotynski, Urban Emmenegger, Sebastien Hotte, et al.European Journal of Cancer (Oxford, England : 1990)|December 23, 2025
Feasibility of ctDNA-guided precision neoadjuvant therapy in locally advanced rectal cancer: Insights from the ongoing CINTS-R trialXiao Zhang, Jiaolin Zhou, Jianhao Geng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate CancerCatherine H Marshall, Wei Fu, Hao Wang, et al.Journal of Medicinal Chemistry|July 28, 2009
Design, synthesis, and structure-activity relationship of tropane muscarinic acetylcholine receptor antagonistsDramane I Lainé, Zehong Wan, Hongxing Yan, et al.Journal of Medicinal Chemistry|July 28, 2025
Structure-Activity Relationship of <i>N</i>-Cyclopropylmethyl-7α-[<i>para</i>-(arylcarboxamido)phenyl]-6,14-<i>endo</i>ethano-tetrahydronorthebaines as Potent and Selective Kappa Opioid Receptor AgonistsLinghui Kong, Songyu Yao, Denggao Zhang, et al.JCO Precision Oncology|May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 InhibitorsEmmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.Allergy|November 13, 2020
Risk factors for severe and critically ill COVID-19 patients: A reviewYa-Dong Gao, Mei Ding, Xiang Dong, et al.JAMA Oncology|December 16, 2021
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical TrialYansong Lin, Shukui Qin, Zhiyong Li, et al.Pageof 176